ReViral

London, United Kingdom Founded: 2011 • Age: 15 yrs Acquired By Pfizer
Antiviral compounds for Respiratory Syncytial Virus infections are developed.

About ReViral

ReViral is a Healthcare company based in London (United Kingdom) founded in 2011 by Khattereh Ahmadi, and was acquired by Pfizer in April 2022. Antiviral compounds for Respiratory Syncytial Virus infections are developed. ReViral has raised $176 million across 5 funding rounds from investors including Pfizer, New Leaf Venture Partners and Orbimed. The company has 28 employees. The company was acqui-hired. ReViral offers products and services including Backorder Service and Auction Platform. Its focus areas include Life Sciences, Pulmonology, Drugs and Lung Infections. Its legal entity is REVIRAL LIMITED.

Company details

ReViral was founded in 2011 and is based in London, United Kingdom. Operations are conducted in the biotechnology sector, where antiviral compounds targeting Respiratory Syncytial Virus (RSV) are developed. The lead candidate, RV521, is progressed as a therapy for RSV infections, which frequently result in complications such as asthma, chronic obstructive pulmonary disease, or pneumonia. Focus is placed on advancing treatments for respiratory conditions.

  • Headquarters London, United Kingdom
  • Employees 28
  • Founders Khattereh Ahmadi
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website reviral.co.uk
  • Social X
  • Acquired by Pfizer (Apr 2022)
  • Legal Name Reviral Limited
  • Date of Incorporation 10 Jan, 2011
  • Jurisdiction SANDWICH, KENT, ENGLAND
Key Metrics
  • Annual Revenue
    $19.68 M (USD)
    as on Dec 31, 2016
  • Net Profit
    -$8.3 M (USD)
    9
    as on Dec 31, 2018
  • Total Equity Funding
    $176M (USD)

    in 5 rounds

  • Latest Funding Round
    $44M (USD), Series C

    Aug 2020

  • Investors
    Pfizer

    & 8 more

  • Employee Count
    28
  • Acquired by
    Pfizer

    (Apr 2022)

Products & Services of ReViral

ReViral offers a comprehensive portfolio of products and services, including Backorder Service and Auction Platform.

Backorder Service
Domain Acquisition

Enables backordering of expiring UK domains for automatic registration.

Auction Platform
Domain Auctioning

Facilitates bidding on domains with multiple backorders.

Funding Insights of ReViral

ReViral has successfully raised a total of $176M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $44 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $176M
  • Total Rounds 5
  • Last Round Series C β€” $44M
  • First Round $1M

    (Dec 2014)

  • Investors Count 8

All 5 funding rounds of ReViral with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2020$44MSeries C––
Aug 2018$55MSeries B–New Leaf Venture Partners, Novo Holdings
Jul 2018$55MSeries B–New Leaf Venture Partners, Novo Holdings
Sep 2015$21MSeries A––
Dec 2014$1MSeed––
Valuation history

9 investors in total: 9 institutional.

Investors in ReViral

ReViral has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, New Leaf Venture Partners and Orbimed.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Capital is provided to firms for growth, buyouts, and acquisitions.
2001anderapartners.comParis, France
Health-tech companies are targeted for venture capital investments.
1999perceptivelife.comNew York, United States
Brace Pharma Capital is focused on investing in innovative therapies.
bracepharma.comAtlanta, United States
Private equity investments and corporate advisory services are managed.
greensandsequity.comSan Francisco, United States
Stage-agnostic investments in US life sciences are managed.
2005nlvpartners.comNew York, United States
Private equity and venture capital fund focused on the healthcare sector
novoholdings.dkHellerup, Denmark
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Wellcome is a global charitable foundation focused on health research.
wellcome.ac.ukLondon, United Kingdom
Pharmaceutical products for treating multiple diseases are provided.
1849pfizer.comNew York, United States
Premium access

Investor details for ReViral

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of ReViral

13 people are tracked at ReViral (5 in leadership, 8 in board & advisors); the tracked headcount is 28.

NameRoleGroup
Khattereh Ahmadi
Co-FounderLeadership
Edward Littler
Executive DirectorLeadership
Alex C. Sapir
CEOLeadership
Eddy Littler
COOLeadership
Cora Griffin
Head, Business Development & Alliance ManagementLeadership
Chau Q. Khuong
DirectorBoard & advisors
Lawrence Blatt
Non-Executive DirectorBoard & advisors
Jason Zhou
DirectorBoard & advisors
Richard N. Kender
Non-Executive DirectorBoard & advisors
Ron Hunt
DirectorBoard & advisors
Ken Powell
ChairmanBoard & advisors
Iain D. Dukes
Non-Executive DirectorBoard & advisors
Raphaël Wisniewski
DirectorBoard & advisors
Premium access

Complete people profiles for ReViral

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of ReViral

4 dated milestones of ReViral across 11 years, from founding to its latest funding, stage changes and deals.

  1. Founded ReViral is founded.
  2. Funding First funding round of $1.0M.
  3. Funding Latest funding round, Series C, of $44.0M.
  4. Exit Acquired by Pfizer.

Top companies in Genomics & Gene Therapy Platforms

2 companies that operate in the same segment as ReViral (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Nanopore-based electronic systems for single-molecule analysis are developed.
2005Oxford, Oxfordshire, United KingdomUSD 1.34 BUSD 301.49 M1,372
Genetically modified cell lines are developed using AAV gene-editing platform.
2007Cambridge, Cambridgeshire, United KingdomUSD 46.29 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Reviral

Premium access

Complete news archive for ReViral

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ReViral

ReViral was founded in 2011 and raised its 1st funding round 3 years after it was founded.

ReViral is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

ReViral is a funded company, having raised a total of $176M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Dec 2014.

ReViral has 28 employees.

Annual revenue of ReViral is $19.68M as on Dec 31, 2016.

ReViral was founded in 2011 and is based in London, United Kingdom. Operations are conducted in the biotechnology sector, where antiviral compounds targeting Respiratory Syncytial Virus (RSV) are developed. The lead candidate, RV521, is progressed as a therapy for RSV infections, which frequently result in complications such as asthma, chronic obstructive pulmonary disease, or pneumonia. Focus is placed on advancing treatments for respiratory conditions.

ReViral offers Backorder Service and Auction Platform.

ReViral has 9 investors. Key investors include Pfizer, New Leaf Venture Partners, Orbimed, Andera Partners, and Perceptive Advisors.

ReViral operates through Reviral Limited.

Yes. ReViral was acquired by Pfizer in April 2022.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available